Adherex Appoints Two Independent Directors

RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwire) – April 28, 2014 – Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced the appointment of Dr. Khalid Islam and Adrian Haigh to the Company’s Board of Directors, effective immediately.  With these additions, the Adherex Board is now comprised of five directors, four of whom are independent. “We welcome […]

Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at Asco Meeting

– COG STUDY ACCL0431 oral presentation for hearing protection in rare childhood cancers – SIOPEL 6 poster presentation for hearing protection in standard risk hepatoblastoma RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwire) – April 22, 2014) – Adherex Technologies, Inc. (TSX:AHX, OTC: ADHXF) today announced that both of the Phase III studies being conducted on Sodium Thiosulfate (STS) […]

Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2013 Financial Results

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Mar 31, 2014) – Adherex Technologies Inc. (AHX.TO)(ADHXF), today reported its financial results and recent developments for the year ended December 31, 2013. All amounts are in US dollars unless otherwise specified. The two Phase 3 clinical trials studying Sodium Thiosulfate (STS) for prevention of hearing loss in children receiving […]

Adherex Announces Sodium Thiosulfate Clinical Study Update

RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Feb 27, 2014) – Adherex Technologies, Inc. (AHX.TO)(ADHXF) today announced that the Children’s Oncology Group (COG), posted top line results on http://clinicaltrials.gov/ under Study ACCL0431, A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children. No statistical analysis was published and a full analysis of all […]